Related Experiment Video
Updated: Jan 30, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
EZH2 directs HER2+ breast cancer progression through the modulation of epithelial plasticity
Linshan Liu1,2, Ellie J Massey1,2, Dongmei Zuo2
1Department of Biochemistry, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
Abstract:
Breast cancer remains a leading cause of death among women, with the HER2+ subtype being particularly aggressive due to acquired resistance to HER2-targeted therapies. Enhancer of Zeste Homolog 2 (EZH2), the catalytic subunit of Polycomb Repressive Complex 2, represses the expression of genetic programs crucial for differentiation, proliferation, and apoptosis. To investigate the role of EZH2 in HER2+ tumor progression, we crossed a genetically engineered mouse model of HER2-driven breast cancer with a conditional Ezh2 knockout strain and showed that Ezh2 is essential for accelerating tumor initiation and metastatic dissemination. Combined bulk and single cell RNA sequencing analyses revealed a significant downregulation of basal cell populations in the absence of Ezh2, and an upregulation of luminal progenitor cell populations, driven by crucial transcription factors such as Esr1. Further, inhibition of EZH2 in vitro resulted in increased expression of ER in HER2+ human breast cancer cell lines and conferred sensitivity to Tamoxifen. These findings demonstrate that EZH2 dictates cancer plasticity and provides rationale for combining EZH2 inhibitors with endocrine therapies to improve HER2+ breast cancer outcomes.
Insights
Enhancer of Zeste Homolog 2 (EZH2) drives aggressive HER2+ breast cancer progression and metastasis. Inhibiting EZH2 increases estrogen receptor expression, making tumors sensitive to endocrine therapies like Tamoxifen.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- HER2-positive (HER2+) breast cancer is aggressive and develops resistance to targeted therapies.
- Enhancer of Zeste Homolog 2 (EZH2) regulates gene expression critical for cell function.
- EZH2's role in HER2+ breast cancer progression and therapy resistance is not fully understood.
Purpose of the Study:
- To investigate the role of EZH2 in HER2+ breast cancer initiation and metastasis.
- To determine how EZH2 influences cellular plasticity and gene expression in HER2+ tumors.
- To evaluate the therapeutic potential of combining EZH2 inhibition with endocrine therapy.
Main Methods:
- Utilized a genetically engineered mouse model of HER2+ breast cancer with conditional Ezh2 knockout.
- Performed bulk and single-cell RNA sequencing to analyze gene expression changes.
- Investigated EZH2 inhibition effects on HER2+ human breast cancer cell lines in vitro.
Main Results:
- Ezh2 deficiency accelerated tumor initiation and metastatic dissemination in mice.
- Loss of Ezh2 led to decreased basal cell populations and increased luminal progenitor populations, involving Esr1.
- In vitro EZH2 inhibition increased estrogen receptor (ER) expression and tamoxifen sensitivity in HER2+ cells.
Conclusions:
- EZH2 plays a critical role in driving cancer cell plasticity in HER2+ breast cancer.
- Targeting EZH2 may overcome resistance to HER2-targeted therapies.
- Combining EZH2 inhibitors with endocrine therapies offers a promising strategy to improve treatment outcomes for HER2+ breast cancer.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Plasticity
Plasticizers
Plasticizers function by using surface-active agents to create repulsive electrostatic forces between cement particles. This dispersion enhances the concrete's...
Plastic Behavior
Plastic Deformations
Plastic Deformations

